Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSFORM-1: Navitoclax + Ruxolitinib vs Ruxolitinib in Myelofibrosis
jRCT2041210045Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in myelofibrosis (MF) comparing Navitoclax + Ruxolitinib with Placebo for Navitoclax + Ruxolitinib (2 arms). Primary endpoint: Percentage of participants with spleen volume reduction ≥35% at week 24 (SVR35W24). Started Jul 2021; status: active, not recruiting.
02
Drugs
navitoclax
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on jRCT2041210045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210045.